SCOLR Pharma Inc.(fka SCLR)

[StockWhisperer]

Ask and Bid closing up.....getting thin! $SCLR

[BCNstocks]

SCLR awesome!

SCLR..003 falling,.008 next.ACTIVE SOS NOW

Weeeeeeee, check the new SOS

[ash111]

Weeeeeeee, check the new SOS

[BCNstocks]

SCLR only 10k at .003!

SCLR..003 falling,.008 next.ACTIVE SOS NOW

[ash111]

We gonna fly.updates coukd hit,anyday per SOS

[BCNstocks]

Bid moving UP!!!

SCLR

[StockWhisperer]

$SCLR.........best buy before major bounce! Cheap at this price!

[ash111]

SCLR now active under WA SOS: http://www.sos.wa.gov/corps/search_results.aspx?search_type=simple&criteria=all&name_type=contains&name=olr&ubi=


SCOLR PHARMA, INC.

View Additional Information »
Purchase Documents for this Corporation »
UBI Number 601664951
Category REG
Profit/Nonprofit Profit
Active/Inactive Active
State of Incorporation DE
WA Filing Date 10/17/1995
Expiration Date 10/31/2013
Inactive Date
Duration Perpetual
Registered Agent Information

[BCNstocks]

SCLR only 64k cap,49m o/s 52 wk.range:.0012:.13,no RS's ~ .003 falling! SCLR is waaaaay oversold! HUGE BOUNCE commencing!!!

[StockWhisperer]

Let the run begin?!!!! $SCLR

[ash111]

looks interesting here,only 64k cap,49m o/s 52 wk.range:.0012:.13,no RS's

[StockWhisperer]

Will move up fast when it does! :)

[0001]

Board is getting kinda busy. Maybe this company will spring back to life, give it a little CPR

[BCNstocks]

SCLR .0013 waaaaay oversold! HOY is .13 (no r/s!) and loy this week is .0012. Watch for a HUGE BOUNCE here! Chart:

http://stockcharts.com/h-sc/ui?s=SCLR

[Bucks79]

dang, that l2 is crazy thin, almost nothing to .008. just sit back and wait for some material event and watch it run.

[Bucks79]

people grabbing cheapies before someone takes this ticker over. real thin to .008

[TheFinalCD]

Item 2.04 Triggering Events that Accelerate or Increase A Direct Financial Obligation or an Off-Balance Sheet Arrangement.

SCOLR Pharma, Inc., a Delaware corporation (the “Company”), ceased its business operations on March 1, 2013. The cessation of operations may constitute an event of default under the Company’s outstanding 8% Senior Secured Convertible Debentures due June, 2013. The Company has $2,545,200 principal amount outstanding under the debentures.

The Debentures are secured by all the Company’s assets pursuant to a Security Agreement dated June 16, 2011 among the Company and CSC Trust Company of Delaware as collateral agent (the “ Security Agreement ”). Upon certain events of default, the holders of the Debentures may be entitled to accelerate the Company’s obligations under the Debentures and exercise available remedies under the Security Agreement.

Following an event of default, interest on the Debentures accrues at a rate of 18% per annum.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In connection with the cessation of its operations described in Item 2.04 above, the Company terminated its remaining employees, including its Chief Executive Officer, Stephen J. Turner, effective March 1, 2013.


SOURCE: http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9132974

[Bucks79]

volume breakout as well doesn't hurt.

[Bucks79]

low risk, high reward grabbing some under half a penny , a lot of room to run. $SCLR

[BCNstocks]

Only 41k left on the ask at .0034 and then showing .005! Very thin back up to pennies. SCLR hoy is .13

[Bucks79]

nice bounce play, bought a starter $SCLR

[BCNstocks]

SCLR .0026 ~ hoy is .13 ~ very thin ~ could see a nice bounce here!

[HDOGTX]

sure is, on watch.....

[Wabi]

XxxmarkedXxxx easy mover

[02opida]

Green

[mikenmtv]

Turner should be ashamed....How many years has he lived off of others like a parasite? Traded this 5 years ago......sad to see so many people lose money and be mislead for so long!

[bigblue72]

Company is dead, read from 8K.........
SCOLR Pharma, Inc., a Delaware corporation (the “Company”), ceased its business operations on March 1, 2013. The cessation of operations may constitute an event of default under the Company’s outstanding 8% Senior Secured Convertible Debentures due June, 2013. The Company has $2,545,200 principal amount outstanding under the debentures.
The Debentures are secured by all the Company’s assets pursuant to a Security Agreement dated June 16, 2011 among the Company and CSC Trust Company of Delaware as collateral agent (the “Security Agreement”). Upon certain events of default, the holders of the Debentures may be entitled to accelerate the Company’s obligations under the Debentures and exercise available remedies under the Security Agreement.
Following an event of default, interest on the Debentures accrues at a rate of 18% per annum.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In connection with the cessation of its operations described in Item 2.04 above, the Company terminated its remaining employees, including its Chief Executive Officer, Stephen J. Turner, effective March 1, 2013.

[kzivann]

Why the drop?

[stockrookiehere]

Interesting gonna put this on Radar, especially with the latest patent news...

[stockspirit]

December 23, 2011 at 9:35 am

SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products

BOTHELL, Wash. , Dec. 23, 2011 /PRNewswire/ — SCOLR Pharma, Inc. (OTCQB: SCLR.OB - News) today announced that it has received and shipped initial retail orders for its extended-release nutritional products based on the Company’s proprietary CDT® oral drug delivery platform. The shipments represent SCOLR’s first significant direct retail sales of its nutritional products. Stephen J. Turner , SCOLR Pharma’s President and CEO, said, “Shipment of these initial orders marks an important milestone for SCOLR as we continue to focus on growing our nutritional products business into a sustainable source of revenue. We are gratified by the response we have had with retailers and confident that our products are greeted well by consumers.”

Turner said SCOLR intends to provide investors with future updates on its nutritional business activities in conjunction with its quarterly announcements of financial results and in its periodic reports filed with the Securities and Exchange Commission.

About SCOLR Pharma:

Based in Bothell, Washington , SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

[stockspirit]

February 15, 2012 at 11:24 am

SCOLR Pharma’s Partner to Commence Bioequivalence Study of Ondansetron

BOTHELL, Wash., Feb. 14, 2012 /PRNewswire/ — SCOLR Pharma, Inc. (OTCQB: SCLR.OB - News) announced today that RedHill Biopharma Ltd., a license partner that had previously obtained the exclusive worldwide rights to use SCOLR’s patented technology to develop a new version of ondansetron, will conduct a bioequivalence trial in Canada. Both the US Food and Drug Administration (FDA) and Health Canada have reviewed the protocol for the study and have no objections.

RedHill submitted an Investigational New Drug application (IND) to the FDA and a Clinical Trial Application (CTA) to Health Canada seeking permission to compare the bioequivalence of its product, which it calls RHB-102, to Zofran® (ondansetron), which is manufactured by GlaxoSmithKline. Zofran® is an anti-emetic drug (i.e. for prevention of nausea and vomiting) that is administered several times per day. RHB-102 is a once-daily controlled release tablet formulation of ondansetron, a serotonin 5-HT3 receptor antagonist.

RedHill Biopharma said publicly, based on advice received from its regulatory consultants, that subject to certain conditions, the study may be considered a pivotal trial (Phase III-equivalent) that may be used by the Company for a marketing application to the FDA. RedHill Biopharma estimated the development costs of RHB-102, until submission of an application to the FDA, will total $2-3 million.

Stephen Turner, President and CEO of SCOLR, said: “We believe that the RedHill Biopharma announcement again affirms the potential value of SCOLR’s patented technology in developing new pharmaceuticals that improve on existing drugs. We look forward to a successful outcome on this study and a promising ongoing relationship with RedHill.”

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

About RedHill Biopharma Ltd.:

RedHill Biopharma is an emerging Israeli biopharmaceutical company focused primarily on development and acquisition of late clinical-stage new formulations of existing drugs. The Company’s current product pipeline includes a once-daily formulation of a leading congestive heart failure and high blood pressure drug, a once-daily formulation of a leading radiotherapy induced nausea and vomiting prevention drug, an oral thin film formulation of a leading triptan for the treatment of acute migraine, a combination therapy for the treatment of MAP infection in Crohn’s as well as a companion diagnostic test for detection of the MAP bacteria, a combination treatment of resistant H. pylori bacteria causing ulcers, and a patent protected encapsulated formulation for bowel preparation ahead of certain gastro procedures. The Company’s team includes prominent pharmaceutical experts. For more information please visit: www.redhillbio.com.

[stockspirit]

I thought this would be a great time to start a new board for SCLR since the company is also starting to become a revenue generating business.
Not only are we finally starting to sell our nutraceauticals in large retailers, but I have been informed that we are also getting re-orders. It's taken a long time to get here, but let's hope that SCLR has arrived and will grow from here.